Ameriprise
VBIV

Ameriprise’s VBI Vaccines, Inc. New Common Stock (Canada) VBIV Stock Holding History

Ameriprise’s Portfolio VBIV Stock Details VBIV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-450
Closed -$4.09K – 4025
2023
Q1 		$4.09K Sell
450
-478
-52% -$6.77K ﹤0.01% 3928
2022
Q4 		$11K Sell
928
-629
-40% -$11.1K ﹤0.01% 3926
2022
Q3 		$33K Sell
1,557
-320
-17% -$8.63K ﹤0.01% 3910
2022
Q2 		$46K Buy
1,877
+232
+14% +$7.89K ﹤0.01% 3831
2022
Q1 		$82K Buy
1,645
+2
+0.1% +$99 ﹤0.01% 3863
2021
Q4 		$115K Sell
1,643
-767
-32% -$64.6K ﹤0.01% 3862
2021
Q3 		$225K Sell
2,410
-34
-1% -$3.23K ﹤0.01% 3676
2021
Q2 		$246K Hold
2,444
– – ﹤0.01% 3702
2021
Q1 		$228K Buy
2,444
+1,713
+234% +$174K ﹤0.01% 3676
2020
Q4 		$60K Buy
731
+277
+61% +$23.6K ﹤0.01% 3716
2020
Q3 		$39K Buy
+454
New +$52.9K ﹤0.01% 3686

Other funds holding VBIV

PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GAI
General American Investors New York $1.69B AUM 40.94% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Ameriprise's VBIV Position: Q2 2023 in Review

Ameriprise sold out of VBI Vaccines, Inc. New Common Stock (Canada) (VBIV) in Q2 2023, closing a stake of 450 shares — an estimated $4.09K sold.

Ameriprise first reported a position in VBIV in Q3 2020 and held it in 11 quarters. The position peaked at $246K in Q2 2021. 46 funds tracked by Wall St. Rank hold VBIV as of Q2 2023.

  • Ameriprise reported no remaining VBI Vaccines, Inc. New Common Stock (Canada) position as of Q2 2023 after selling out during the quarter.
  • Ameriprise sold 450 VBI Vaccines, Inc. New Common Stock (Canada) shares in Q2 2023, an estimated $4.09K.
  • Ameriprise first reported a position in VBI Vaccines, Inc. New Common Stock (Canada) in Q3 2020 and held it in 11 quarters.
  • Ameriprise's VBI Vaccines, Inc. New Common Stock (Canada) position peaked at $246K in Q2 2021.
  • 46 funds tracked by Wall St. Rank held VBI Vaccines, Inc. New Common Stock (Canada) as of Q2 2023.

Based on Ameriprise's 13F filing for Q2 2023, filed 14 Aug 2023.